Biostage wins $1.1M second phase NIH grant
Photo | Courtesy
Biostage CEO Jim McGorry.
Holliston biotech Biostage has been awarded $1.1 million as part of a second phase of a fast-track small business grant to help the company’s throat implant products make it to market.
The grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health will help the company develop and test its Cellspan Esophageal Implant to treat of throat defects in small babies.
The company hopes its science can help treat esophageal atresia in children, which is a gap between the upper and lower esophagus that causes health complications.
The company’s Cellframe technology is intended to act as a scaffolding and help regenerate the esophagus, and it could become the standard of care for the condition, CEO Jim McGorry said in a press release.
“Our scientific advisory board, comprised of esteemed pediatric surgeons, believes our technology will provide a novel approach to treating these underserved kids,” he said.
The company is working with the U.S. Food and Drug Administration to advance the company’s technology to clinical trials after completing the first $225,000 phase of the grant in March.
The $1.1 million in phase two will support development and testing through September. Another $500,000 is potentially available for the following year.
WBJ Web Partners
Most Recent
Most Recent
0 Comments